Trial Profile
Navigated Laser In Branch Retinal Vein Occlusion Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Branch retinal vein occlusion; Diabetic macular oedema; Retinal oedema
- Focus Therapeutic Use
- Acronyms NIRVANA
- 24 Oct 2022 Results (n=41) evaluating if combination treatment of navigated central retinal laser and aflibercept lowered the treatment burden in these patients,published in the Acta Ophthalmologica
- 18 Apr 2022 Status changed from active, no longer recruiting to completed.
- 03 Mar 2021 Planned number of patients changed from 60 to 47.